Tirzepatide's Innovative Applications in the Management of Type 2 Diabetes and Its Future Prospects in Cardiovascular Health

Overview

Journal Front Pharmacol

Date 2024 Sep 12

PMID 39263564

Authors

Jingqi Yang

Yuncheng Gu

Huaigang Chen

Hong Wang

Lang Hong

Bin Li

Liu Yang

Affiliations

Soon will be listed here.

Abstract

Tirzepatide, a novel GLP-1/GIP dual receptor agonist, shows significant advantages in glycemic management and weight control. By summarizing the results of the SURMOUNT and SURPASS clinical trials, we evaluate the efficacy and safety of tirzepatide in reducing blood glucose and weight. These trials indicate that tirzepatide significantly lowers HbA1c levels (with a maximum reduction of 2.24%) and promotes weight loss (up to 11.2 kg) with good tolerability. However, there are still some challenges in its clinical application, including high treatment costs and gastrointestinal discomfort. Additionally, the safety and efficacy of tirzepatide in special populations, such as patients with renal impairment, require further investigation. Future large-scale clinical trials, such as SURPASS-CVOT and SUMMIT, are expected to further verify the long-term benefits of tirzepatide in cardiovascular health management, providing stronger evidence for its comprehensive treatment of diabetes and its complications.

Citing Articles

The Gut Microbiome's Influence on Incretins and Impact on Blood Glucose Control.

Dulai A, Min M, Sivamani R Biomedicines. 2025; 12(12.

PMID: 39767626 PMC: 11727616. DOI: 10.3390/biomedicines12122719.

References

Rosenstock J, Frias J, Rodbard H, Tofe S, Sears E, Huh R . Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. JAMA. 2023; 330(17):1631-1640. PMC: 10548360. DOI: 10.1001/jama.2023.20294. View

Ogurtsova K, Guariguata L, Barengo N, Ruiz P, Sacre J, Karuranga S . IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2021; 183:109118. DOI: 10.1016/j.diabres.2021.109118. View

Patel H, Khunti K, Rodbard H, Bajaj H, Bray R, Kindracki Z . Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. 2023; 26(2):473-481. DOI: 10.1111/dom.15333. View

Gao L, Lee B, Chawla M, Kim J, Huo L, Du L . Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023; 29(6):1500-1510. DOI: 10.1038/s41591-023-02344-1. View

Tashiro Y, Sato K, Watanabe T, Nohtomi K, Terasaki M, Nagashima M . A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides. 2014; 54:19-26. DOI: 10.1016/j.peptides.2013.12.015. View

Willard F, Douros J, Gabe M, Showalter A, Wainscott D, Suter T . Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020; 5(17). PMC: 7526454. DOI: 10.1172/jci.insight.140532. View

Xia T, He W, Luo Z, Wang K, Tan X . Achyranthes bidentata polysaccharide ameliorates type 2 diabetes mellitus by gut microbiota-derived short-chain fatty acids-induced activation of the GLP-1/GLP-1R/cAMP/PKA/CREB/INS pathway. Int J Biol Macromol. 2024; 270(Pt 2):132256. DOI: 10.1016/j.ijbiomac.2024.132256. View

Heerspink H, Sattar N, Pavo I, Haupt A, Duffin K, Yang Z . Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022; 10(11):774-785. DOI: 10.1016/S2213-8587(22)00243-1. View

Urva S, Quinlan T, Landry J, Martin J, Loghin C . Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clin Pharmacokinet. 2021; 60(8):1049-1059. PMC: 8332596. DOI: 10.1007/s40262-021-01012-2. View

10.

Nauck M, Meier J . Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018; 20 Suppl 1:5-21. DOI: 10.1111/dom.13129. View

11.

Buse J, Wexler D, Tsapas A, Rossing P, Mingrone G, Mathieu C . 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019; 43(2):487-493. PMC: 6971782. DOI: 10.2337/dci19-0066. View

12.

Velenosi T, Urquhart B . Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol. 2014; 10(8):1131-43. DOI: 10.1517/17425255.2014.931371. View

13.

Wilding J, Batterham R, Calanna S, Davies M, Van Gaal L, Lingvay I . Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384(11):989-1002. DOI: 10.1056/NEJMoa2032183. View

14.

Koshibu M, Mori Y, Saito T, Kushima H, Hiromura M, Terasaki M . Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms. Am J Physiol Endocrinol Metab. 2019; 316(5):E895-E907. DOI: 10.1152/ajpendo.00511.2018. View

15.

Papamargaritis D, Al-Najim W, Lim J, Crane J, Bodicoat D, Barber S . Effectiveness of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in weight management services (STRIVE study): a multicentre, open-label, parallel-group, randomized controlled trial. Lancet Reg Health Eur. 2024; 39:100853. PMC: 11129336. DOI: 10.1016/j.lanepe.2024.100853. View

16.

Lim C, Pasternak B, Eliasson B, Danaei G, Ueda P . Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol. 2022; 30(8):634-643. DOI: 10.1093/eurjpc/zwac315. View

17.

Nicholls S, Bhatt D, Buse J, Del Prato S, Kahn S, Lincoff A . Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2023; 267:1-11. DOI: 10.1016/j.ahj.2023.09.007. View

18.

Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino D . Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2021; 134(1):14-19. DOI: 10.1080/00325481.2021.2002616. View

19.

Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D . Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10402):613-626. DOI: 10.1016/S0140-6736(23)01200-X. View

20.

Frias J, Davies M, Rosenstock J, Perez Manghi F, Lando L, Bergman B . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515. DOI: 10.1056/NEJMoa2107519. View